H3K27M mutations, ANGPT1, and the blood-brain barrier in DIPG
Regulation of Angpt1 and DIPG blood-brain barrier integrity by H3K27M mutations
This work looks at how the H3K27M mutation changes ANGPT1 and the tumor blood–brain barrier in high-grade brain tumors like DIPG to help drugs reach tumors more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11234308 on NIH RePORTER |
What this research studies
Researchers will use mouse models and human tumor tissue to measure ANGPT1 levels and blood–brain barrier function across different glioma subtypes. They will study how the H3K27M mutation alters ANGPT1-Tie2 signaling and the vascular response within tumors. Methods include in utero electroporation-created mouse models, lab tests of barrier leakiness, molecular analysis of tumor samples, and comparison with human tumor data. The team aims to identify mechanisms that could be targeted to improve delivery of therapies to these tumors.
Who could benefit from this research
Good fit: People with high-grade gliomas—especially diffuse midline gliomas or tumors known to carry H3K27M mutations—would be most relevant for tissue donation or related clinical collaborations.
Not a fit: Patients without high-grade brain tumors, without H3K27M mutations, or those seeking immediate therapeutic benefit should not expect direct benefit from this research.
Why it matters
Potential benefit: If successful, this work could point to ways to make cancer drugs reach brain tumors more reliably by targeting ANGPT1-Tie2 pathways.
How similar studies have performed: Targeting vascular signaling to improve drug delivery has shown promise in preclinical brain tumor work, but focusing on ANGPT1/Tie2 in H3K27M-associated DIPG is a newer and less-tested approach.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Phoenix, Timothy N — University of Cincinnati
- Study coordinator: Phoenix, Timothy N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.